Condition: Colorectal Cancer · Sponsor: Fudan University
This randomized phase II trial evaluates the efficacy of long-course chemoradiotherapy (50Gy/25Fx + capecitabine) versus short-course radiotherapy (25Gy/5Fx) combined with CAPOX（Capecitabine and Oxaliplatin）, PD-1 inhibitor (serplulimab), and COX-2 inhibitor (celecoxib) in MSS（MicroSatellite Stable） locally advanced rectal cancer, with primary endpoint of complete response rate (pCR+cCR)（Complete Remission） and secondary endpoints including anal preservation rate and 3-year survival outcomes, aiming to elucidate the immunomodulatory effects of triple therapy on tumor microenvironment.
This description comes directly from the study's public registry record.
Dawei Li · +86-021-64175590 · li_dawei@fudan.edu.cn
Always discuss trial participation with your own doctor first.
| Fujian Provincial Cancer Hospital | Fuzhou, Fujian, China | Recruiting |
| Anyang Tumor Hospital | Anyang, Henan, China | Recruiting |
| The First Affiliated Hospital of Shandong First Medical University | Jinan, Shandong, China | Recruiting |
| Yunnan Cancer Hospital | Kunming, China | Recruiting |
| Fudan University Shanghai Cancer Center | Shanghai, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07154316